Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System raised its stake in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 1.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 222,900 shares of the company’s stock after buying an additional 3,600 shares during the period. California Public Employees Retirement System owned approximately 0.18% of Ionis Pharmaceuticals worth $11,301,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of IONS. Vanguard Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 4.4% in the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after buying an additional 417,364 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Ionis Pharmaceuticals by 33.0% in the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after buying an additional 284,266 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Ionis Pharmaceuticals by 40.2% in the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after buying an additional 281,733 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Ionis Pharmaceuticals by 4.0% in the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock valued at $347,135,000 after buying an additional 264,179 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new position in shares of Ionis Pharmaceuticals in the second quarter valued at $4,629,000. 91.40% of the stock is currently owned by institutional investors.

Shares of Ionis Pharmaceuticals Inc (IONS) opened at $53.17 on Friday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. Ionis Pharmaceuticals Inc has a one year low of $37.26 and a one year high of $65.51. The stock has a market cap of $6,610.00, a price-to-earnings ratio of 379.79 and a beta of 2.86.

In other news, COO B Lynne Parshall sold 16,118 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $1,047,670.00. Following the transaction, the chief operating officer now directly owns 33,526 shares in the company, valued at approximately $2,179,190. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP C Frank Bennett sold 12,250 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $796,250.00. Following the transaction, the senior vice president now owns 27,291 shares in the company, valued at $1,773,915. The disclosure for this sale can be found here. Over the last three months, insiders have sold 102,781 shares of company stock worth $5,733,330. Company insiders own 2.13% of the company’s stock.

Several research analysts have issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Barclays dropped their price target on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $50.76.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares Bought by California Public Employees Retirement System” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/01/12/ionis-pharmaceuticals-inc-ions-stake-raised-by-california-public-employees-retirement-system.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply